ES
MARKETS / NASDAQ / SEPN
NASDAQ · PHARMACEUTICAL PREPARATIONS

Septerna, Inc. SEPN

3 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$46.0M
▲ 4174.5% vs FY2024
EPS · FY25
$-1.10
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-12.2%
Net margin · FY25
-106.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 46.0M
Revenue, FY2025 · full 3-year series below
Revenue Net income
0.020.040.060.0-0.020232025
0.020.040.060.0-0.020232025

The company lost 106 cents on every revenue dollar this year.

Per share
USD -1.10
Diluted EPS, FY2025
EPS
0.40.81.2-1.1020232025
0.40.81.2-1.1020232025

The company pays no cash dividend.

Profitability
-12.2%
Return on equity, FY2025
ROE
0.250.50.751-12.2%20232025
0.250.50.751-12.2%20232025
Operating margin-148.6%
Net margin-106.4%
Return on assets-9.3%

Each USD of equity lost 12 cents this year.

Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.04B
Shares outstanding, FY2025
0.000.0420232025
0.000.0420232025
Change, 5 years—
Change, 10 years—

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 596.2M
total assets, end of FY2025
Total assetsUSD 596.2M
EquityUSD 381.9M
CashUSD 120.7M
Current ratio4.73×

Equity funds 64% of total assets.

History
3 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
Revenue $B
0.0
0.0
0.0
Operating income $B
−0.1
−0.1
−0.0
EBITDA $B
−0.1
−0.1
−0.0
Income tax $B
0.0
−0.0
0.0
Net income $B
−0.0
−0.1
0.0
EPS, diluted $
−1.10
−7.26
0.29
Dividend / sh $
·
·
·
Payout %
·
·
·
ROE %
−12.2
−37.6
·
Shares out B
0.04
0.04
0.00

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
9 of 9
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed